

Figure S1. (A-F) The expression of TRIP13 in (A-C) LUAD and (D-F) LUSC based on histological subtypes, nodal metastasis status and individual patient's age. TRIP13, thyroid hormone receptor interactor 13; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.




Figure S2. (A and B) TRIP13 expression in HCC827 (treated with 0.5 μ M gefitinib for 12 h), HCC827GR and H1975 cells (treated with 5 μ M gefitinib for 12 h) transfected with TRIP13 or shTRIP13. (C) TRIP13 expression in LUAD with or without alterations to the mTOR pathway. TRIP13, thyroid hormone receptor interactor 13; LUAD, lung adenocarcinoma; mTOR, Mechanistic target of rapamycin; NC, negative control cells; sh-, short hairpin; DMSO, dimethyl sulfoxide; GEFI, gefitinib.

